WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. C型肝炎ウイルス感染に対する肝移植 liver transplantation for hepatitis c virus infection
2. C型肝炎ウイルス感染と腎移植 hepatitis c virus infection and renal transplantation
3. B型肝炎ウイルスの特性および感染の病因 characteristics of the hepatitis b virus and pathogenesis of infection
4. 肝内胆管の消失および胆管消失症候群 hepatic ductopenia and vanishing bile duct syndrome
5. 慢性B型肝炎ウイルス感染に対する肝移植 liver transplantation for chronic hepatitis b virus infection

Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.

Leroy V1, Dumortier J2, Coilly A3, Sebagh M3, Fougerou-Leurent C4, Radenne S5, Botta D6, Durand F7, Silvain C8, Lebray P9, Houssel-Debry P10, Kamar N11, D'Alteroche L12, Petrov-Sanchez V13, Diallo A13, Pageaux GP14, Duclos-Vallee JC3; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO23 Compassionate Use of Protease Inhibitors in Viral C in Liver Transplantation Study Group.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.Clin Gastroenterol Hepatol.2015 Nov;13(11):1993-2001.e1-2. doi: 10.1016/j.cgh.2015.05.030. Epub 2015 Jun 1.
BACKGROUND & AIMS: Fibrosing cholestatic hepatitis (FCH) is a life-threatening disorder that develops in patients with recurrent hepatitis C virus (HCV) infection after liver transplantation. Until recently, therapeutic options have been limited. We evaluated the efficacy and safety of sofosbuvi
PMID 26044317

Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.

Saab S1,2, Jimenez M2, Bau S2, Goo T1, Zhao D3, Durazo F1,2, Han S1,2, El Kabany M1,2, Kaldas F2, Tong MJ2,4, Busuttil RW2.
Clinical transplantation.Clin Transplant.2015 Sep;29(9):813-9. doi: 10.1111/ctr.12584. Epub 2015 Aug 21.
BACKGROUND: Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients.METHODS: We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent
PMID 26147216

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Charlton M1, Everson GT2, Flamm SL3, Kumar P4, Landis C5, Brown RS Jr6, Fried MW7, Terrault NA8, O'Leary JG9, Vargas HE10, Kuo A11, Schiff E12, Sulkowski MS13, Gilroy R14, Watt KD15, Brown K16, Kwo P17, Pungpapong S18, Korenblat KM19, Muir AJ20, Teperman L21, Fontana RJ22, Denning J23, Arterburn S23, Dvory-Sobol H23, Brandt-Sarif T23, Pang PS23, McHutchison JG23, Reddy KR24, Afdhal N25; SOLAR-1 Investigators.
Gastroenterology.Gastroenterology.2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15.
BACKGROUND & AIMS: There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease.METHODS: In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosb
PMID 25985734

横山仁,山下竜也,酒井明人,金子周一
日本アフェレシス学会雑誌 29(3), 253-258, 2010-10-31
… Double filtration plasmapheresis (DFPP) can selectively remove high-molecular substances including hepatitis C virus (HCV) according to the second membrane pore size. … VRAD achieved a high complete early virological reduction (cEVR), and sustained virological response (SVR) even in chronic hepatitis C patients having a high HCV-RNA of difficult-to-treat genotype 1b. …
NAID 110007880248

嶋村剛,谷口雅彦,太田稔,鈴木友己,山下健一郎,古川博之,松下通明,藤堂省
日本アフェレシス学会雑誌 28(2), 125-132, 2009-05-31
… Recurrence of hepatitis C is a lingering problem in liver transplantation (LTx) for hepatitis C-associated hepatocellular carcinoma. … Since a double filtration plasmapheresis (DFPP) theoretically removes hepatitis C virus (HCV), we applied this modality as a prophylactic treatment to 6 recipients with a high-titer of HCV (>1,000KIU/mL). …
NAID 110007326980